6/5
01:21 am
nbix
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum [Yahoo! Finance]
6/4
06:01 pm
nbix
Neurocrine Biosciences (NBIX) was upgraded by
Weiss Ratings from "hold (c+)" to "buy (b-)".
Medium
Report
Neurocrine Biosciences (NBIX) was upgraded by
Weiss Ratings from "hold (c+)" to "buy (b-)".
6/4
01:13 pm
nbix
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX) [Yahoo! Finance]
Low
Report
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX) [Yahoo! Finance]
6/3
08:02 pm
nbix
Neurocrine Biosciences to Present New Two-Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient-Reported Outcome Measures at ENDO 2026 [Yahoo! Finance]
Low
Report
Neurocrine Biosciences to Present New Two-Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient-Reported Outcome Measures at ENDO 2026 [Yahoo! Finance]
6/3
08:30 am
nbix
Neurocrine Biosciences to Present New Two-Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient-Reported Outcome Measures at ENDO 2026
Medium
Report
Neurocrine Biosciences to Present New Two-Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient-Reported Outcome Measures at ENDO 2026
6/2
01:53 pm
nbix
Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript [Seeking Alpha]
Low
Report
Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript [Seeking Alpha]
6/2
08:00 am
nbix
Neurocrine Biosciences (NBIX) had its "buy" rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $213.00 price target on the stock.
Medium
Report
Neurocrine Biosciences (NBIX) had its "buy" rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $213.00 price target on the stock.
5/29
12:43 pm
nbix
Neurocrine Biosciences (NBIX) had its price target raised by Royal Bank Of Canada from $180.00 to $183.00. They now have an "outperform" rating on the stock.
Low
Report
Neurocrine Biosciences (NBIX) had its price target raised by Royal Bank Of Canada from $180.00 to $183.00. They now have an "outperform" rating on the stock.
5/27
11:23 am
nbix
Neurocrine Biosciences: Quantitative Stock of the Week [Barron's]
Low
Report
Neurocrine Biosciences: Quantitative Stock of the Week [Barron's]
5/26
04:43 pm
nbix
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June [TheStreet.com]
Low
Report
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June [TheStreet.com]
5/26
04:01 pm
nbix
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
Low
Report
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
5/25
07:58 pm
nbix
Bernstein Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform [Yahoo! Finance]
Low
Report
Bernstein Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform [Yahoo! Finance]
5/25
07:56 pm
nbix
Bernstein Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform [Yahoo! Finance Canada]
Low
Report
Bernstein Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform [Yahoo! Finance Canada]
5/22
09:00 am
nbix
Neurocrine Biosciences (NBIX) is now covered by Sanford C. Bernstein. They set an "outperform" rating and a $221.00 price target on the stock.
Low
Report
Neurocrine Biosciences (NBIX) is now covered by Sanford C. Bernstein. They set an "outperform" rating and a $221.00 price target on the stock.
5/21
01:37 am
nbix
A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains Attention [Yahoo! Finance]
Low
Report
A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains Attention [Yahoo! Finance]
5/18
04:16 pm
nbix
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules [TheStreet.com]
Low
Report
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules [TheStreet.com]
5/18
04:05 pm
nbix
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Low
Report
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
5/18
09:37 am
nbix
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics [TheStreet.com]
Low
Report
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics [TheStreet.com]
5/18
08:46 am
nbix
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Low
Report
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
5/14
07:11 am
nbix
4basebio Announces Appointment of Chief Financial Officer and Board Changes [Yahoo! Finance]
Medium
Report
4basebio Announces Appointment of Chief Financial Officer and Board Changes [Yahoo! Finance]
5/8
02:04 pm
nbix
Neurocrine Biosciences (NBIX) had its price target raised by JPMorgan Chase & Co. from $177.00 to $185.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NBIX) had its price target raised by JPMorgan Chase & Co. from $177.00 to $185.00. They now have an "overweight" rating on the stock.
5/7
08:07 pm
nbix
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why [Yahoo! Finance]
Low
Report
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why [Yahoo! Finance]
5/7
11:59 am
nbix
Neurocrine Biosciences (NBIX) had its price target raised by Truist Financial Corporation from $140.00 to $155.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NBIX) had its price target raised by Truist Financial Corporation from $140.00 to $155.00. They now have a "buy" rating on the stock.
5/6
06:25 pm
nbix
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside [Seeking Alpha]
Low
Report
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside [Seeking Alpha]
5/6
02:51 pm
nbix
Neurocrine Biosciences (NBIX) had its price target raised by Morgan Stanley from $185.00 to $191.00. They now have an "equal weight" rating on the stock.
Low
Report
Neurocrine Biosciences (NBIX) had its price target raised by Morgan Stanley from $185.00 to $191.00. They now have an "equal weight" rating on the stock.